MESO - Mesoblast Ltd logo

MESO

Mesoblast Ltd

Net β€”top 1%Rev β€”top 1%10Y

Mesoblast Ltd develops regenerative medicine products utilizing mesenchymal lineage cells. Its lead candidate, Remestemcel-L, targets systemic inflammatory diseases and chronic conditions. The company collaborates on various therapies for heart failure and arthritis.

βš•οΈ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 20 years ago β†’$66,001today

Score Overview

1 Year
Scoreβ€”
Net Growthβ€”
Net Trendβ€”
Net Income Consistencyβ€”
Rev Growthβ€”
Rev Trendβ€”
Revenue Consistencyβ€”
5 Years
Scoreβ€”
Net Growthβ€”
Net Trend50%
Net Income Consistencyβ€”
Rev Growthβ€”
Rev Trend50%
Revenue Consistencyβ€”
10 Years
Scoreβ€”
Net Growthβ€”
Net Trend44%
Net Income ConsistencyInconsistent
Rev Growthβ€”
Rev Trend44%
Revenue Consistency1%
All Time
Scoreβ€”
Net Growthβ€”
Net Trend44%
Net Income ConsistencyInconsistent
Rev Growthβ€”
Rev Trend44%
Revenue Consistency4%

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-05-22
$ 15.20β€”
1 Year2025-05-22
$ 10.8340.35%
5 Years2021-05-21
$ 15.041.06%
10 Years2016-05-20
$ 14.147.50%
20 Years2006-03-27
$ 0.2366x
All Time2015-11-13
$ 16.22-6.29%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 129M
2025$ 17M-$ 102M$ 161M
2024$ 5M-$ 87M$ 62M
2023$ 7M-$ 81M$ 70M
2022$ 10M-$ 91M$ 60M
2021$ 7M-$ 98M$ 136M
2020$ 32M-$ 77M$ 129M
2019$ 16M-$ 89M$ 50M
2018$ 17M-$ 35M$ 37M
2017$ 2M-$ 76M$ 45M
2016$ 42M-$ 4M$ 21M